TY - JOUR
T1 - Sex disparities in presentation and prognosis of 1110 patients with hepatocellular carcinoma
AU - Rich, Nicole E.
AU - Murphy, Caitlin Claffey
AU - Yopp, Adam C.
AU - Tiro, Jasmin
AU - Marrero, Jorge A
AU - Singal, Amit G.
N1 - Funding Information:
: Jorge A. Marrero has served as a consultant for Glycotest and received research funding from AstraZeneca. Amit G. Singal has been on advisory boards and served as a consultant for Wako Diagnostics, Roche, Exact Sciences, Glycotest, Bayer, Eisai, Exelixis BMS, Merck and TARGET‐Pharmasolutions. Nicole E. Rich, Caitlin C. Murphy, Adam C. Yopp and Jasmin Tiro have no relevant conflicts of interest. Declaration of personal interests
Funding Information:
Dr Singal's research is supported by National Cancer Institute R01 CA222900 and R01 MD12565. This research was supported in part by NIH UL‐1TR001105 and CTSA NIH UL‐1 RR024982. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Funding Information:
Dr Singal's research is supported by National Cancer Institute R01 CA222900 and R01 MD12565. This research was supported in part by NIH UL-1TR001105 and CTSA NIH UL-1 RR024982. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Declaration of personal interests: Jorge A. Marrero has served as a consultant for Glycotest and received research funding from AstraZeneca. Amit G. Singal has been on advisory boards and served as a consultant for Wako Diagnostics, Roche, Exact Sciences, Glycotest, Bayer, Eisai, Exelixis BMS, Merck and TARGET-Pharmasolutions. Nicole E. Rich, Caitlin C. Murphy, Adam C. Yopp and Jasmin Tiro have no relevant conflicts of interest.
Publisher Copyright:
© 2020 John Wiley & Sons Ltd
PY - 2020/8
Y1 - 2020/8
N2 - Background: Although sex disparities in hepatocellular carcinoma (HCC) incidence have been well described, there are limited data examining sex disparities in HCC prognosis. Aim: To characterise sex differences in HCC presentation and prognosis. Methods: We performed a retrospective study of consecutive patients (n = 1110, 23.5% women) diagnosed with HCC between 2008 and 2017 at two US health systems. We used Cox proportional hazard and multivariable logistic regression models to identify factors associated with overall survival, early tumour detection and response to HCC treatment (per the modified Response Evaluation Criteria in Solid Tumors [mRECIST] criteria). Results: Women were older at HCC diagnosis (mean 62.5 vs 59.2 years, P < 0.001) and had a higher proportion of early-stage tumours (53.1% vs 43.7% Barcelona Clinic Liver Cancer [BCLC] stage 0/A, P = 0.04), but similar liver function compared to men (49.2% vs 47.1% Child Pugh A, P = 0.27). In univariable analysis, women had significantly better overall survival than men (median 17.1 vs 12.0 months, P = 0.02). When stratified by age, younger (<65 years) women had better overall survival than men (18.3 vs 11.2 months, P = 0.02); however, older (≥65 years) women and men had similar overall survival (15.5 vs 15.7 months, P = 0.45). In multivariable analysis, female sex was independently associated with lower mortality after adjusting for age, race/ethnicity, alpha-fetoprotein, BCLC stage, Albumin-Bilirubin grade and Child Pugh score (hazard ratio [HR] 0.82, 95% confidence interval [CI] 0.68-0.98). In secondary analyses, female sex was independently associated with early tumour detection (odds ratio [OR] 1.46, 95% CI 1.05-2.02) and response to first HCC treatment (OR 1.72, 95% CI 1.18-2.53) after adjusting for the same covariates. Conclusion: In a large cohort of patients with HCC, women had significantly better prognosis than men.
AB - Background: Although sex disparities in hepatocellular carcinoma (HCC) incidence have been well described, there are limited data examining sex disparities in HCC prognosis. Aim: To characterise sex differences in HCC presentation and prognosis. Methods: We performed a retrospective study of consecutive patients (n = 1110, 23.5% women) diagnosed with HCC between 2008 and 2017 at two US health systems. We used Cox proportional hazard and multivariable logistic regression models to identify factors associated with overall survival, early tumour detection and response to HCC treatment (per the modified Response Evaluation Criteria in Solid Tumors [mRECIST] criteria). Results: Women were older at HCC diagnosis (mean 62.5 vs 59.2 years, P < 0.001) and had a higher proportion of early-stage tumours (53.1% vs 43.7% Barcelona Clinic Liver Cancer [BCLC] stage 0/A, P = 0.04), but similar liver function compared to men (49.2% vs 47.1% Child Pugh A, P = 0.27). In univariable analysis, women had significantly better overall survival than men (median 17.1 vs 12.0 months, P = 0.02). When stratified by age, younger (<65 years) women had better overall survival than men (18.3 vs 11.2 months, P = 0.02); however, older (≥65 years) women and men had similar overall survival (15.5 vs 15.7 months, P = 0.45). In multivariable analysis, female sex was independently associated with lower mortality after adjusting for age, race/ethnicity, alpha-fetoprotein, BCLC stage, Albumin-Bilirubin grade and Child Pugh score (hazard ratio [HR] 0.82, 95% confidence interval [CI] 0.68-0.98). In secondary analyses, female sex was independently associated with early tumour detection (odds ratio [OR] 1.46, 95% CI 1.05-2.02) and response to first HCC treatment (OR 1.72, 95% CI 1.18-2.53) after adjusting for the same covariates. Conclusion: In a large cohort of patients with HCC, women had significantly better prognosis than men.
UR - http://www.scopus.com/inward/record.url?scp=85087174582&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85087174582&partnerID=8YFLogxK
U2 - 10.1111/apt.15917
DO - 10.1111/apt.15917
M3 - Article
C2 - 32598091
AN - SCOPUS:85087174582
VL - 52
SP - 701
EP - 709
JO - Alimentary Pharmacology and Therapeutics
JF - Alimentary Pharmacology and Therapeutics
SN - 0269-2813
IS - 4
ER -